ROC curves for PFS and OS.

<p>The ROC curves for 1-year (A) and 2-year (B) PFS of the risk score estimated by Cox regression indicate a substantially improved correlation with 1-year and 2-year PFS. The ROC curves for 1-year (C) and 2-year (D) OS are also shown.</p

Kaplan-Meier analysis of PFS and OS after stratification by IgG titer against selected EGFR-derived peptides in NSCLC patients receiving gefitinib treatment.

<p>Kaplan-Meier plots of PFS (A) and OS (B) in patients showing higher and lower IgG titers against the selected peptides, egfr_41_ 60, egfr_61_80, and egfr_481_500, are shown. Lower and higher IgG titers were defined by their median values.</p

Patients' characteristics.

<p>Patients' characteristics.</p

Cox regression analysis of PFS for NSCLC patients.

<p>Cox regression analysis of PFS for NSCLC patients.</p

Multivariate analysis of OS.

<p>Multivariate analysis of OS.</p

Multivariate analysis of PFS.

<p>Multivariate analysis of PFS.</p

Relation between expression score for ERCC1 and various patient characteristics.

a<p>Determined by Fisher’s exact test.</p

Multivariate analysis of OS.

<p>Multivariate analysis of OS.</p

Immunohistochemical assessment of ERCC1 and correlation between ERCC1 and survival.

<p>A: Expression of ERCC1 was assessed by immunohistochemistry. Expression of ERCC1 protein was detected in the nuclei of cancer cells (x400). B: Kaplan-Meier survival curves according to ERCC1 expression score. C: ERCC1-negative patients with exon 19 deletion had longer PFS than the others, and ERCC1-positive patients without exon 19 deletion had shorter PFS than the others.</p

Multivariate analysis of PFS.

<p>Multivariate analysis of PFS.</p